Intercept Pharmaceuticals (Intercept Pharmaceuticals) Accumulated Depreciation : $-1.3 Mil (As of Sep. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Intercept Pharmaceuticals Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Intercept Pharmaceuticals's quarterly accumulated depreciation declined from Mar. 2023 ($-3.9 Mil) to Jun. 2023 ($-1.2 Mil) but then increased from Jun. 2023 ($-1.2 Mil) to Sep. 2023 ($-1.3 Mil).

Intercept Pharmaceuticals's annual accumulated depreciation increased from Dec. 2020 ($-16.9 Mil) to Dec. 2021 ($-18.1 Mil) but then stayed the same from Dec. 2021 ($-18.1 Mil) to Dec. 2022 ($-3.8 Mil).

Intercept Pharmaceuticals Accumulated Depreciation Historical Data

The historical data trend for Intercept Pharmaceuticals's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercept Pharmaceuticals Accumulated Depreciation Chart

Intercept Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Accumulated Depreciation

Get a 7-Day Free Trial

-11.95

-13.71

-16.88

-18.13

-3.80

Intercept Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Accumulated Depreciation	Get a 7-Day Free Trial															-3.71	-3.80	-3.89	-1.23	-1.33

Intercept Pharmaceuticals Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Intercept Pharmaceuticals Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Intercept Pharmaceuticals's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Intercept Pharmaceuticals (Intercept Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intercept Pharmaceuticals Inc (NAS:ICPT) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

N/A

Address

305 Madison Avenue, Morristown, NJ, USA, 07960

Website

https://www.interceptpharma.com

Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Executives

Andrew Saik	officer: EVP & Chief Financial Officer	640 LEE ROAD, CHESTERBROOK PA 19087
M Michelle Berrey	officer: President, R&D and CMO	303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Dagmar Rosa-bjorkeson	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Rocco Venezia	officer: Chief Accounting Officer	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001
Srinivas Akkaraju	director	565 EVERETT AVENUE, PALO ALTO CA 94301
Lisa Defrancesco	officer: SVP, IR & Corp. Affairs	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Linda M Richardson	officer: EVP & Chief Commercial Officer	2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713
Jared Freedberg	officer: General Counsel and Secretary	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Bryan Ball	officer: Chief Quality Officer	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Sandip Kapadia	officer: CFO and Treasurer	450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011
Jason Campagna	officer: Chief Medical Officer	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Paolo Fundaro	director, 10 percent owner	C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123
Francesco Micheli	10 percent owner	C/O GENEXTRA S.P.A., VIA G. DE GRASSI, 11, MILAN L6 20124
Genextra S.p.a.	10 percent owner	VIA G. DE GRASSI, 11, MILAN L6 20123
Keith Michael Gottesdiener	director	900 FIFTH AVENUE, #8C, NEW YORK NY 10021